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ABSTRACT:
Labelled 5α-dihydrotestosterone (DHT) binding experiments have shown that 
expression levels of (yet unidentified) membrane androgen receptors (mAR) are 
elevated in prostate cancer and correlate with a negative prognosis. However, 
activation of these receptors which mediate a rapid androgen response can counteract 
several cancer hallmark functions such as unlimited proliferation, enhanced migration, 
adhesion and invasion and the inability to induce apoptosis. Here, we investigate the 
downstream signaling pathways of mAR and identify rapid DHT induced activation 
of store-operated Ca2+ entry (SOCE) in primary cultures of human prostate epithelial 
cells (hPEC) from non-tumorous tissue. Consequently, down-regulation of Orai1, the 
main molecular component of Ca2+ release-activated Ca2+ (CRAC) channels results in 
an almost complete loss of DHT induced SOCE. We demonstrate that this DHT induced 
Ca2+ influx via Orai1 is important for rapid androgen triggered prostate specific antigen 
(PSA) release. We furthermore identified alterations of the molecular components 
of CRAC channels in prostate cancer. Three lines of evidence indicate that prostate 
cancer cells down-regulate expression of the Orai1 homolog Orai3: First, Orai3 mRNA 
expression levels are significantly reduced in tumorous tissue when compared to non-
tumorous tissue from prostate cancer patients. Second, mRNA expression levels of 
Orai3 are decreased in prostate cancer cell lines LNCaP and DU145 when compared 
to hPEC from healthy tissue. Third, the pharmacological profile of CRAC channels in 
prostate cancer cell lines and hPEC differ and siRNA based knock-down experiments 
indicate changed Orai3 levels are underlying the altered pharmacological profile. 
The cancer-specific composition and pharmacology of CRAC channels identifies CRAC 
channels as putative targets in prostate cancer therapy. 
INTRODUCTION
In classical steroid receptor pathways, hormones 
cross the plasma membrane and bind to their cytosolic 
receptors. Subsequently, these complexes translocate to 
the nucleus where they trigger gene expression important 
for many physiological and pathophysiological functions 
and thus are targets for therapeutic strategies [1-3]. In 
contrast to the classical pathway where the hormonal 
effects appear after hours, many cell types display rapid 
hormone signaling upon steroid hormone stimulation 
mediated by receptors or ion channels located at the cell 
surface [4, 5]. 
Even though the molecular identity of mAR is 
still elusive, their presence has been demonstrated in the 
membrane of primary prostate tissue and was correlated 
to the level of differentiation of prostate carcinoma [6, 7]. 
mAR are existent in androgen-sensitive prostate cancer 
cell line LNCaP [8] as well as in androgen-insensitive 
prostate cancer cell lines DU145 and PC3 [9, 10]. 
Rapid DHT signaling results in rearrangements of the 
cytoskeleton, PSA production, inhibition of proliferation, 
migration, adhesion and invasion and apoptotic regression 
of prostate cancer cells [8, 11, 12]. Several studies in mice 
demonstrated the clinical relevance of targeting mAR in 
prostate cancer therapy. Macroscopic tumors are reduced 
upon treatment with testosterone-albumin conjugates, 
binding exclusively to mAR. In addition, testosterone-BSA 
triggers tumor cell apoptosis as the fraction of apoptotic 
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cells in tumorous tissue is elevated. Co-medication of 
mice with paclitaxel and testosterone-BSA results in 
additive tumor inhibitory rates up to ~92% [11, 12]. Taken 
together, targeting mAR pathways in prostate cancer is a 
highly promising strategy especially as no toxic effects 
of testosterone-albumin conjugates have been reported in 
these studies [13].
As a universal mechanism rapid androgen 
signaling includes an increase in intracellular Ca2+ as 
second messenger [4]. Previous work proposed that the 
mAR induced increase in intracellular Ca2+ arises from 
intracellular Ca2+ store depletion and the Ca2+ influx via 
voltage gated Ca2+ channels in the plasma membrane in 
LNCaP cells [14]. 
During the last few years the molecular components 
of SOCE and the underlying Ca2+ current ICRAC (Ca2+ 
release-activated Ca2+ current) have been identified: 
stromal interaction molecule STIM1 [15, 16] and plasma 
membrane protein Orai1 [17-19]. Upon Ca2+ release from 
intracellular Ca2+ stores, Ca2+ dissociates from an EF hand 
motif in the luminal section of STIM1. STIM1 molecules 
cluster and activate Ca2+ influx via Orai1 ion channels in 
the plasma membrane [20-24]. A number of studies of the 
STIM1 homologue STIM2 and the Orai1 homologues 
Orai2 and Orai3 increasingly reveal disease related roles 
for these less prominent but ubiquitously expressed 
isoforms [25].
ICRAC mediates a plethora of cellular functions 
including cell cycle regulation, proliferation and apoptosis 
[26]. In prostate cancer, Ca2+ signaling via ICRAC channels 
is decreased and subsequently, the low ICRAC contributes 
to cancer hallmark functions in particular uninhibited 
proliferation and the inability to induce apoptosis [27-29]. 
In addition, low expression levels of Orai1 can protect 
LNCaP cells from several apoptotic pathways [30].
Here, we investigate the role of ICRAC channel 
components in Ca2+ signaling in the rapid response to DHT 
stimulation. We compare expression levels of STIM1, 
STIM2, Orai1, Orai2 and Orai3 in tumorous and non-
tumorous tissue from prostate cancer patients. In addition, 
we examine the pharmacological profile of ICRAC in hPEC 
from non-tumorous tissue and prostate cancer cell lines 
LNCaP and DU145 to investigate ICRAC‘s molecular key 
players as potential therapeutic targets. 
RESULTS
DHT induces SOCE in hPEC
First, we investigate the molecular key players in 
androgen induced Ca2+ signaling in hPEC. Application of 
100 nM DHT in Ca2+ free solution induces a substantial 
increase in intracellular Ca2+ due to Ca2+ release from 
intracellular Ca2+ stores as has been described earlier [14]. 
The subsequent addition of 2 mM Ca2+ induced a rapid 
increase in intracellular Ca2+ concentration thus confirming 
that DHT induces SOCE in hPEC. Control cells on which 
no DHT has been applied release Ca2+ from intracellular 
Ca2+ stores to some extent, possibly induced by the Ca2+ 
free solution. But both, Ca2+ release from intracellular Ca2+ 
stores and SOCE are almost reduced to zero in control 
cells (Figure 1A). Supplementary Figure 1A shows that 
store-depletion by sarco-/endoplasmic reticulum Ca2+-
ATPase (SERCA) inhibitor thapsigargin (tg) evokes 
SOCE, confirming the principle mechanism of SOCE in 
hPEC.
Adenosine-5’-triphosphate (ATP) has been 
described as signal molecule for prostate epithelial cells 
[31] as well as melatonin [32]. Application of 100 µM 
ATP activates SOCE but 1 µM melatonin does not (Figure 
1B) suggesting that ATP induced signaling includes SOCE 
pathways whereas melatonin signaling pathways do not.
Please note that basal Ca2+ levels vary between 100 
nM and 200 nM (Figure 1A and 1B and Supplementary 
Figure 1A) most likely as data were generated with cell 
preparations from different patients.
Based on these initial findings we analysed gene 
expression levels of CRAC channel components Orai1, 
Orai2, Orai3, STIM1 and STIM2 by qRT-PCR in hPEC 
from 17 different patients (Figure 1C and Supplementary 
1B). Our data suggest that CRAC channels in hPEC are 
mainly formed by STIM1 and Orai1. Figure 1D represents 
the ratio of Orai1:Orai3 and STIM1:Orai1 expression 
pointing towards an STIM1:Orai1 ratio of 4.6±0.4, 
which, assuming a linear correlation between mRNA and 
protein levels would be above optimal for maximal SOCE 
activation [33] and a relatively low Orai1:Orai3 ratio of 
4.3±0.5 (for comparison, the Orai1:Orai3 ratio is ~70 in 
naïve and ~25 in effector TH cells, [34]). The latter points 
towards a contribution of approximately one Orai3 subunit 
to the functional CRAC channel, that has been described 
as either tetramer [35-40] or hexamer [41] in the past.
The down-regulation of the SOCE component 
Orai1 by siRNA significantly reduced the Ca2+ influx 
rate and peak of SOCE and the Ca2+ plateau is decreased 
when compared to SOCE in cells transfected with non-
silencing control RNA (Figure 1E, F, G and H). The down-
regulation of Orai3 had little effect on the Ca2+ influx rate 
and peak of SOCE, but significantly increased the Ca2+ 
plateau (Figure 1E, F, G and H). Knock-down efficiencies 
are shown in Fig. S1c. In order to investigate if down-
regulation of Orai1 or Orai3 leads to differences in Ca2+ 
release from intracellular Ca2+ stores, we subtracted base 
lines from DHT induced Ca2+ peaks in 0 Ca2+ for single 
cells and analysed the averages. The differences in the 
degree of store depletion are not significant (Figure 1I).
In conclusion, these data show that rapid DHT 
response involves Ca2+ signaling via ICRAC channels and 
indicate a key role for Orai1 whereas the function of Orai3 
is less clear.
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Molecular components of ICRAC mediate rapid 
DHT response 
In order to investigate molecular components of 
DHT induced SOCE, we used the prostate cancer cell 
line LNCaP. In a siRNA based assay in LNCaP cells that 
were cultured in hormone deprived media for 48 h, down-
regulation of SOCE components STIM1, STIM2, Orai1, 
Orai3 or Orai1 and Orai3 led to an overall decrease of 
DHT induced SOCE when compared to control RNA 
treated cells (solid lines, Figure 2A). Gene expression 
levels and efficiency of down-regulation from cells 
cultured in hormone deprived media for 48 h are shown 
in Supplementary Figure 2A and B. Down-regulation 
of STIM1, Orai1, Orai3 or Orai1 and Orai3 results in a 
significant decrease of Ca2+ influx rate (Figure 2B), Ca2+ 
peak (Figure 2C) and Ca2+ plateau (Figure 2D) of SOCE. 
Down-regulation of STIM2 significantly increased Ca2+ 
influx rate (Figure 2B), possibly due to a loss of STIM2 
suppressing function of STIM1 as described earlier 
by [42]. Interestingly, STIM2 down-regulation also 
significantly decreased Ca2+ peak (Figure 2C) and Ca2+ 
plateau (Figure 2D) of SOCE. Global store-depletion by 
tg results in a higher Ca2+ signal upon Ca2+ release and 
higher SOCE when compared to DHT induced SOCE 
(black dotted line (tg) versus black solid line (DHT), 
Figure 2A). Down-regulation of Orai3 does not decrease 
but significantly increase Ca2+ influx rate, Ca2+ peak 
and Ca2+ plateau of tg-induced SOCE (Figure 2A and 
supplementary  Figure 2C). 
We next tested for Orai1’s contribution to rapid 
androgen induced PSA release. Rapid DHT signaling 
increased basal PSA production up to 20% in LNCaP 
cells [8]. Comparison of PSA release from LNCaP cells 
transfected with control RNA (0.48±0.08 ng·mL-1·106 
cells-1) or with Orai1 specific siRNA (0.39±0.07 
ng·mL-1·106 cells-1) demonstrates that DHT induced 
PSA release depends on Orai1 whereas long-term gene 
expression (after 24 h) dependent PSA release appears to 
be independent on Orai1 (Figure 2E). In summary, knock-
down molecular components of ICRAC results in decreased 
Ca2+ signaling upon DHT stimulation. Down-regulation 
of main component of CRAC channel component Orai1 
reduces DHT induced PSA release.
Figure 1: SOCE in hPEC. A) Average intracellular Ca2+ responses (±SEM) from a Fura-2 based Ca2+ imaging assay when 100 nM 
DHT, (n = 44) or no stimulus (n = 14) were applied are blotted vs. time. Extracellular Ca2+ concentration is indicated in mM. B) Same 
as A but either 100 µM ATP, n = 37 (black), or 1 µM Melatonin, n = 14 (green) were used as stimulus. C) qRT-PCR analyses of Orai1, 
Orai2, Orai3, STIM1 and STIM2 expression levels from hPEC from 17 different patients normalized to TATA box binding protein (TBP) 
expression as reference gene. D) Ratio of Orai1:Orai3 and STIM1:Orai1 expression levels. E) DHT induced intracellular Ca2+ responses in 
cells transfected with control RNA (black, n = 38), Orai1 siRNA (red, n = 33) or Orai3 siRNA (blue, n = 36). F) Average Ca2+ influx rates 
for cells in E when 2 mM Ca2+ and 100 nM DHT were applied. G) Average of Ca2+ peaks for cells in E when 2 mM Ca2+ and 100 nM DHT 
were applied when baseline for every cell was subtracted. H) Average Ca2+ plateaus for cells in E when 2 mM Ca2+ and 100 nM DHT were 
applied at t = 1600 s and baseline for every cell was subtracted. I) Average Ca2+ peaks after store depletion with 100 nM DHT in Ca2+ free 
Ringer for cells in E when baseline for every cell was subtracted.
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ICRAC exhibits a unique 2-APB specific 
electrophysiological profile in hPEC
Next, we tested for the properties of ICRAC in hPEC 
in patch clamp experiments in order to investigate typical 
electrophysiological hallmarks of ICRAC. We evoked ICRAC in 
a 20 mM Ca2+ Ringer solution by adding 10 mM BAPTA 
and 50 µM inositol-1, 4, 5-trisphosphate (IP3) to the patch 
pipette. In these cells ICRAC is ~ 0.5 – 1 pA/pF (Figure 3A, 
3B and 3C). Application of 0 mM Ca2+ abolishes ICRAC 
(Figure 3A, current-voltage curves IVs shown in Figure 
3D) and upon application of divalent free solution (DVF) 
ICRAC exhibits large inwardly rectified Na+ currents (Figure 
3B, IVs shown in Figure 3E). These characteristics are in 
very good agreement to the literature about native CRAC 
channels (as discussed below). In many native cells as well 
as in STIM1/Orai1 overexpression systems, application of 
2-APB (50 µM) amplifies and subsequently blocks ICRAC 
(EC50 ~3 - 4 µM, IC50 ~ 8 - 10 µM, [43, 44]). Surprisingly, 
the 2-APB specific electrophysiological profile of hPEC 
(Figure 3C and Supplementary Figure 3A, IVs shown 
in Figure 3F and Supplementary Figure 3D and 2-APB 
induced dose-responses Figure 3G and H) differs from 
what is described for native CRAC channels and STIM1/
Orai1 overexpression systems. The EC50 for potentiation is 
~24 µM (Figure 3G) and the IC50 for inhibition is 82 µM 
(Figure 3H). The Orai1:Orai3 ratio in prostate cancer cell 
lines LNCaP und DU145 is elevated compared to hPEC 
(Orai1:Orai3 = 17±0.9, n = 4, in DU145 and Orai1:Orai3 = 
26±0.9, n = 4, in LNCaP calculated from gene expression 
levels shown in Supplementary Figure 4A). Identical to 
the experiment in hPEC (Figure 3C and 3F) we determined 
the 2-APB induced electrophysiological profile in prostate 
cancer cell lines DU145 (Supplementary Figure 3B and 
3E) and LNCaP (Supplementary Figure 3C and 3F). 
The statistical analysis in Figure 3I reveals a significant 
difference in pharmacological profile in DU145 upon 
application of 75 µM 2-APB and a significant difference 
in pharmacological profile in LNCaP upon application of 
50 or 75 µM 2-APB when compared to hPEC from non-
tumorous tissue.
As Orai3 is largely expressed in hPEC we next 
wanted to test if heteromeric Orai1/Orai3 channels might 
be responsible for the 2-APB specific electrophysiological 
Figure 2: Rapid DHT response in LNCaP depends on SOCE. A) Average intracellular Ca2+ responses (±SEM) from a Fura-2 
based Ca2+ imaging assay when stores are depleted by application of 100 nM DHT (solid lines) and cells were transfected with control RNA 
(control, black curve, n = 132), Orai1 siRNA (siO1, red curve, n = 117), Orai3 siRNA (siO3, blue curve, n = 126), Orai1 and Orai3 siRNA 
(siO1+O3, green curve, n = 77), STIM1 siRNA (siS1, purple curve, n = 137), STIM2 siRNA (siS2, brown curve, n = 180), or stores are 
depleted by application of 1 µM tg (dotted line) and cells were transfected with control RNA (control, black curve, n = 228) or Orai3 siRNA 
(siO3, blue curve, n = 227) or stores were not depleted (no stimulus) and transfected with control RNA (pink curve, n = 45). Extracellular 
Ca2+ concentration is indicated in mM. B) Average Ca2+ influx rates from cells in A, when 100 nM DHT and 2 mM Ca2+ were applied. 
C) Average Ca2+ peaks from cells in A, when 100 nM DHT and 2 mM Ca2+ were applied and baseline for every cell was subtracted. D) 
Average Ca2+ plateaus from cells in A, when 100 nM DHT and 2 mM Ca2+ were applied and baseline for every cell was subtracted. E) PSA 
concentration in the media 10 min after stimulation with 100 nM DHT (double determination in n = 5 experiments) and PSA concentration 
in the media 24 h after stimulation with 100 nM DHT (double determination in n = 3 experiments) when cells were transfected with control 
RNA or Orai1 siRNA.
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profile. 
Orai3 is a regulator of SOCE and is responsible 
for the 2-APB specific electrophysiological profile 
of ICRAC in LNCaP cells
Given the extraordinary 2-APB specific 
electrophysiological profile of hPEC (Figure 3), the low 
Orai1:Orai3 ratio of ~4 (Figure 1) and Orai3’s property 
to enhance Ca2+ currents upon 2-APB application [44-48] 
we tested the ability of Orai3 to shape the 2-APB specific 
electrophysiological profile of ICRAC in the prostate cancer 
cell line LNCaP as LNCaP are less delicate to patch after 
transfection than hPEC. When 2-APB is applied in a 
concentration of 30 µM, ICRAC is enhanced and application 
of 50 µM 2-APB results in current enhancement 
followed by an incomplete current block (Figure 4A, 
IVs are shown in Supplementary Figure 4C and 4D) as 
has previously been shown by [49]. In these cells, ICRAC 
exhibits an EC50 of 8 µM (Figure 4B) and an IC50 of 
36 µM (Figure 4C). Figure 4D shows ICRAC in a siRNA 
based assay, when Orai1, Orai3, or both proteins are 
down-regulated. Analysis of IP3 induced currents show, 
that down-regulation of Orai3 significantly increases 
current size, while down-regulation of Orai1 or Orai1 and 
Orai3 significantly decreases the current size (Figure 4D 
and 4E). Upon siRNA based knock-down residual gene 
expression on mRNA level range from 11±5 % to 32±7 % 
(Supplementary Figure 4B).
Whereas ICRAC in control RNA transfected cells 
is amplified upon application of 30 µM 2-APB, down-
regulation of Orai1 or Orai1 and Orai3 results in an almost 
complete loss of 2-APB induced current. The fact that both 
knock-down conditions give the same result implies that 
Orai1 is the stringent requirement for a functional SOCE 
and that in LNCaP cells the CRAC channel likely exists 
as a heteromeric Orai1/Orai3 channel. Down-regulation 
Figure 3: Electrophysiological and pharmacological characterization of ICRAC in hPEC and prostate cancer cell 
lines. A Time course of ICRAC evoked in hPEC by 50 μM IP3 and 10 mM BAPTA in the patch pipette and 20 mM Ca2+ Ringer in the bath. 
A 0 mM Ca2+ Ringer (0 Ca) was applied as indicated by the red bar (n = 4). B Same as in A, but a divalent free (DVF) external Ringer 
was applied as indicated by the red bar (n = 4). C Same as in A, but 2-APB was applied as indicated (n = 5). D corresponding IVs to A. E 
corresponding IVs to B. F corresponding IVs to C. G Current densities when 2-APB was applied were normalized to IP3 induced current 
at t = 80 s in %. 2-APB induced current potentiation was analysed with a dose-response fit function and an EC50 of 24 µM for potentiation 
was determined. H Same as G but 2-APB induced current inhibition was analysed. Data were fitted with a dose-response fit function and an 
IC50 of 82 µM for inhibition was determined. I Statistical analysis of 2-APB induced pharmacological profile of hPEC from cells in Figure 
3C, DU145 (n=6) and LNCaP (n=6) from experiments performed as in Figure 3C.
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of Orai3 introduces a 2-APB induced block of ICRAC that is 
characteristic for STIM1/Orai1 mediated currents (Figure 
4F). Thus, high expression levels of Orai3 shape a unique 
pharmacological profile for SOCE and Ca2+ signaling 
via specific CRAC channels in prostate cancer could be 
manipulated by substances selective for a specific channel 
composition.
Relative gene expression of STIM1, STIM2, 
Orai1, Orai2 and Orai3 in non-tumorous and 
tumorous tissue from 13 patients with different 
Gleason score
We were interested in possible changes of ICRAC 
component expression levels in prostate cancer as ICRAC 
is reduced in prostate cancer resulting in several cancer 
hallmark functions. We thus determined relative STIM 
and Orai expression levels in non-tumorous and tumorous 
tissue from 13 prostate cancer patients by qRT-PCR, from 
which 13 expressed detectable levels of STIM1, STIM2 
and Orai1 and 11 detectable levels of Orai2 and Orai3 
(see methods). We find an over-all down-regulation of all 
ICRAC components when gene expression is normalized 
to TBP (Figure 5A, 5B, 5C, 5D and 5E) or RNAPol 
(Supplementary Figure 5A, 5B, 5C, 5D and 5E). The 
different Gleason scores of prostate cancer tumors is 
indicated by symbols as described in the figure legend. 
For analysis we pooled data from patients with different 
Gleason scores. Orai3 is significantly down-regulated 
when gene expression levels are normalized to TBP 
(Figure 5E, p = 0.03 and p = 0.04 when gene expression 
levels are normalized to RNAPol, Supplementary Figure 
5E). Levels of STIM1:STIM2, STIM1:Orai1, and 
Orai1:Orai3 gene expression ratios are slightly changed in 
tumorous tissue (Figure 5F, 5G and 5I and Supplementary 
Figure 5F, 5G and 5I) whereas the Orai1:Orai2 ratio 
remains unchanged (Figure 5H and Supplementary Figure 
5H).
Our data suggest a down-regulation of ICRAC 
components in prostate cancer and support the concept 
of low Ca2+ signaling in prostate cancer cells. Orai3 
is significantly down-regulated and the decrease in 
Orai1:Orai3 ratio might reflect a different stoichiometry 
of Orai1/Orai3 subunits in CRAC channel that open the 
possibility for specific therapeutic targeting in prostate 
cancer.
DISCUSSION
ICRAC mediates several cellular functions such as 
cell cycle regulation, proliferation and apoptosis [26]. 
In prostate cancer, ICRAC is well-known to be off-balance 
[50] and ICRAC channels together with a variety of other 
Ca2+-transporting enzymes are under investigation as 
therapeutic targets [51, 52]. 
Our results uncover that STIM1 and Orai1 are 
ICRAC‘s major molecular components in hPEC and STIM2, 
Orai2 and Orai3 are also expressed. ICRAC channels are 
thought to exist either as tetramers [35-40] or as hexamers 
[41] and the low Orai1:Orai3 ratio of 4.3 supports the 
Figure 4: 2-APB specific electrophysiological profile of LNCaP cells and the role of Orai3. A) Time course of ICRAC evoked in 
LNCaP cells by 50 μM IP3 and 10 mM BAPTA in the patch pipette and 20 mM Ca2+ Ringer in the bath. 2-APB was applied as indicated (30 
µM, n = 10, black line and 50 µM, n = 10, grey line). B) Dose response for 2-APB induced potentiation, EC50 = 8 µM. C) Dose response for 
inhibition of ICRAC by 2-APB, IC50 =36 µM. D) Time course of ICRAC evoked as in A from LNCap cells transfected with non-silencing control 
RNA (control, black, n = 21), transfected with Orai1 siRNA (O1, red, n = 30), Orai3 siRNA (O3, blue, n = 37) or Orai1 and Orai3 siRNA 
(siO1+O3, green, n = 29). Some of the cells in D are also shown in F. E) Current density at 120 s and statistical analysis for cells from D. 
F) Time-course of ICRAC evoked as described in A when 30 µM 2-APB is applied on cells transfected with control RNA (control, black, n = 
11), transfected with Orai1 siRNA (siO1, red, n=11), Orai3 siRNA (siO3, blue, n = 8) or Orai1 and Orai3 siRNA (siO1+O3, green, n = 9).
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concept of heteromeric Orai1/Orai3 channels in hPEC.
ICRAC in hPEC exhibits high Ca2+ selectivity and 
large monovalent currents in the absence of divalent ions 
comparable to native CRAC currents from Jurkat T cells, 
rat basophilic leukaemia cells (RBL) and mast cells [53-
55]. The 2-APB specific electrophysiological profile in 
hPEC is unique with high EC50 and IC50 values (EC50 = 
24 µM and IC50 = 82 µM) when compared to ICRAC in a 
Jurkat T-cell line (EC50 = 3 µM and IC50 = 10 µM [43]) 
and STIM1 Orai1 overexpression systems (EC50 = 4 µM 
and IC50 = 8 µM [44]). Investigation of the 2-APB specific 
electrophysiological profile in a siRNA based assay in 
LNCaP cells suggest Orai1/Orai3 heteromeric channels as 
molecular basis for this unique pharmacology.
 We find a significant down-regulation of Orai3 
gene expression in tumorous tissue when compared 
to non-tumerous tissue from prostate cancer patients 
and an increased Orai1:Orai3 ratio. In addition, a 
comparison of Orai1:Orai3 gene expression ratios and 
electrophysiological profiles upon application of 2-APB 
in prostate cancer cell lines LNCaP, DU145 and hPEC 
support the idea of low levels of Orai3 in prostate cancer, 
although Orai3 is not reduced per se in cancer. In breast 
cancer tissue, Orai3 is up-regulated when compared 
to healthy tissue and its signaling includes cell cycle 
progression, apoptosis resistance, the mitogen-activated 
protein (MAP) kinase pathway and tumor formation 
[56-59]. The altered composition of CRAC channels 
in prostate cancer with a shift in Orai1:Orai3 ratio and 
distinct pharmacological profiles open the possibility to 
selectively manipulate ICRAC activity in cancer cells (e.g. 
to higher Ca2+ signals and thereby drive cancer cells into 
apoptosis) without effecting Ca2+ signals in non-cancerous 
cells.
Targeting mAR and mAR induced signaling 
pathways is an intriguing strategy in the development of 
therapeutic approaches in prostate cancer [13]. So far, 
the androgen-induced increase of intracellular Ca2+ has 
been proposed to be mediated via Ca2+ store-depletion 
and L-type Ca2+ channels and to involve a pertussis 
sensitive G protein-coupled receptor [14, 60]. Evidence 
has accumulated that mAR activation leads to production 
of IP3 [61] and mAR induced IP3 production leads to 
the binding of IP3 to the IP3 receptor and the subsequent 
release of Ca2+ from intracellular Ca2+ stores [62, 63]. 
In 1992, Hoth and Penner demonstrated that Ca2+ store 
depletion by IP3 triggers ICRAC [64]. Here, we demonstrate 
that rapid DHT signaling induces Ca2+ influx via CRAC 
channels in hPEC and a knock-down of the pore forming 
ICRAC channel subunit Orai1 results in a dramatic reduction 
of mAR induced Ca2+ transients in hPEC. In addition, Ca2+ 
signaling via Orai1 functionally supports PSA release in 
rapid DHT response.
mAR exhibit higher expression levels in human 
prostate carcinoma cells when compared to non-tumorous 
and hyperplastic cells related to the Gleason score of the 
tumor [6, 7]. Higher expression levels of mAR are likely 
to increase store-depletion that is below maximum at DHT 
concentrations of 100 nM in LNCaP cells (compare store-
depletion in Figure 2A, DHT vs tg) due to an elevated IP3 
production. Patch clamp and imaging experiments indicate 
down-regulation of Orai3 results in elevated SOCE and 
ICRAC when Ca2+ stores are heavily depleted by either tg or 
IP3 (Figure 2A, 4D and 4E and Supplementary Figure 2C).
We suggest that high mAR expression levels lead 
to stronger store depletion and in combination with Orai3 
down-regulation to higher Ca2+ signals in prostate cancer. 
Once induced these elevated Ca2+ signals could bear the 
potential to counteract cancer hallmark functions that 
are characterized by low Ca2+ signaling e.g. uninhibited 
Figure 5: Gene expression of STIM1, STIM2, Orai1, Orai2 and Orai3 in healthy and tumorous human prostate tissue. 
Relative gene expression of STIM1 (n = 13), STIM2 (n = 13), Orai1 (n = 13), Orai2 (n = 11) and Orai3 (n = 11) in healthy and tumorous 
tissue from prostate cancer patients normalized to the reference gene TBP and sorted by Gleason Score (= 6,  = 7 and  = 8) (A-E) F) 
STIM1:STIM2 ratio. G) STIM1:Orai1 ratio. H) Orai1:Orai2 ratio. I) Orai1:Orai3 ratio.
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proliferation and inability to induce apoptosis. Thus, 
selective enhancement of ICRAC channels in prostate cancer 
cells can be a promising approach in the development of 
mAR therapy.
At the moment a novel therapeutic approach 
against prostate cancer is tested in a clinical trial [65], tg 
coupled to a chemical cage that is specially cleaved of by 
prostate specific membrane antigen (PSMA) a prostate 
specific protease [66]. This so-called smart bomb is active 
only in prostate cancer cells. ICRAC channels might be 
pharmacologic targets for the treatment of prostate cancer 
if they can be selectively manipulated without affecting 
ICRAC channels in healthy cells. Thus, future therapies 
could include smart bombs on prostate cancer-specific 
ICRAC channels. 
MATERIAL & METHODS
Cell culture and prostate tissue collection
Prostate cancer lines Lymph Node Carcinoma of 
the Prostate (LNCaP) and DU145 were purchased from 
American Type Cell Culture Collection (ATCC, Rockville, 
MD, USA) and cultured with RPMI Medium 1640 (Life 
Technologies) supplemented with 10 % FCS and 1 % Pen/
Strep (Life Technologies).
Prostate tissue was obtained from prostectomy 
specimens (Ethics approval 168/05, Ärztekammer des 
Saarlandes). 
Human prostate epithelial cells (hPEC) were 
isolated with slight modifications according to [67]. 
Pieces from healthy tissues are washed in phosphate buffer 
solution and cut into cubes with a side length of 1 mm and 
placed into cell culture flasks. These small tissue cubes are 
wetted with PrEBM (Prostate Cell Basal Medium, #CC-
3165, Lonza) supplemented with PrEGM Single Quots 
Supplements (#CC-4177, Lonza). Under these conditions 
prostate epithelial cells start to form a layer around the 
tissue piece after 2 to 6 days. After an adequate cell layer 
has been formed, pieces are removed and cells are taken 
in culture. For passaging Cell Dissociation Solution 
(#C5789, Sigma) was used to detach cells and cells were 
not grown in media described above. 
For comparison of expression levels of target 
genes via qRT-PCR in healthy and cancer prostate 
tissues primary prostate adenocarcinoma samples, which 
were obtained after radical prostatectomy from thus far 
untreated prostate cancer patients, were investigated. 
Following prostatectomy, the specimens were dissected 
by a pathologist, snap frozen, and stored at −80°C. Only 
samples containing >50% tumor cells were included in the 
study. In the present subset of 13 prostate cancer samples 
were classified with Gleason score as indicated. 
Quantitative RealTime-PCR (qRT-PCR)
Total RNA from LNCaP, DU145 and hPEC was 
isolated with TRIzol Reagent (Life Technologies) 
and from prostate cancer tissue with RNeasy Mini kit 
(Qiagen). For reverse transcription 0.8 µg of isolated total 
RNA was used. 
0.5 µl complementary DNA (cDNA) and 300 
nM primer were used in a QuantiTect SYBRgreen kit 
(Qiagen). PCR conditions were as follows: 15 min at 
95°C; 45 cycles, 30 s at 95°C; 45 s at 58°C; and 30 s at 
72°C and finally a cycle (60 s, 95°C; 30 s 55°C; 30 s 95°C) 
to determine specificity by a dissociation curve using the 
MX3000 cycler (Stratagene). Expression of target genes 
were normalized to the expression of the reference genes 
RNA polymerase II (RNAPol, NM_000937) and/or TATA 
box binding protein (TBP, NM_003194). Primer sequences 
were as follows for Orai1 5’atgagcctcaacgagcact3’ 
(forward) and 5’gtgggtagtcgtggtcag3’ (reverse), 
for Orai3 were 5’gtaccgggagttcgtgca3’ (forward) 
and 5’ggtactcgtggtcactct3’ (reverse), for STIM1 
were 5’ cagagtctgcatgaccttca 3’ (forward) and 
5’ gcttcctgcttagcaaggtt 3’ (reverse), for STIM2 
were 5’ gtctccattccaccctatcc 3’ (forward) and 5’ 
ggctaatgatccaggaggtt 3’ (reverse), TBP were 5’ 
cggagagttctgggattgt 3’ (forward) and 5’ ggttcgtggctctcttatc 
3’ (reverse) and RNAPol were 5’ ggagattgagtccaagttca 3’ 
(forward) and 5’ gcagacacaccagcatagt 3’ (reverse). 
Ca2+ Imaging
Bath solution contained (in mM): 155 NaCl, 4.5 
KCl, 2 MgCl2, 10 glucose, 5 HEPES (pH 7.4 with NaOH), 
and CaCl2 was adjusted as indicated. Stock solutions of 
tg were prepared in DMSO at a concentration of 1 mM 
and of DHT in ethanol at a concentration of 5 mM. For 
Ca2+ imaging assays (see below) LNCaP cells and hPEC 
were cultured for 48 h in hormone deprived RPMI media 
(Sigma R7509), supplemented with 10% charcoal stripped 
FBS (Sigma F6765) and 2 mM L-glutamine, when DHT 
was used as a stimulus. 
Cells were plated on glass cover slips for at least 24 
h and loaded with 1 μM Fura-2/AM at 37°C for 20 min. 
Afterwards glass coverslips were placed in a perfusion 
chamber in a Zeiss Axio Observer.A1 fluorescence 
microscope equipped with a “Plan-Neofluar” 20x/0.4 
objective (Zeiss). The excitation light generated by a 
Polychrome V in a TILL Photonics realtime imaging 
system alternated at 340 and 380 nm and the exposure 
time was set to 50 ms in each channel. Light intensity at 
emission wavelength 440 nm was detected every 5 s and 
digitized by a charge-coupled device camera (Q-Imaging 
Retiga 2000RV). Data was analysed with TILL Vision 
software. Intracellular Ca2+ concentration was calculated 
from the equation [Ca2+]i = K(R − Rmin)/(Rmax – R) in which 
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K, R, Rmin and Rmax where determined in the corresponding 
in situ calibration for hPEC and LNCaP cells according 
to [68].
Electrophysiology
Tight seal whole-cell patch clamp experiments were 
performed with a Patchmaster software controlled EPC-10 
patch-clamp amplifier (HEKA). The fire-polished patch-
pipettes had resistances between 2 and 4 ΩM. Voltage 
ramps of 50 ms duration were delivered every 2 s from a 
holding potential of 0 mV spanning -150 mV to +100 mV 
for hPEC and -150 mV to +150 mV for the LNCaP cells. 
Capacitive currents were determined and corrected before 
each voltage ramp. Current sample rate was 3 kHz and 
data were filtered at 1 kHz. All voltages were corrected 
for a liquid junction potential of −10 mV. For analysis 
leak currents before current activation were subtracted 
and currents extracted at -130 mV and 80 mV and blotted 
vs time. 
The bath solutions contained in mM: 95 NaCl, 2.8 
KCl, 20 CaCl2, 2 MgCl2, 10 HEPES, 10 TEACl, 10 CsCl, 
10 glucose for LNCaP cells and 120 NaCl, 10 TEACl, 20 
CaCl2, 2 MgCl2, 10 HEPES, 10 glucose for hPEC. The 
pH was adjusted with NaOH to 7.2 and osmolarity was 
300 mosmol/L for cell lines and 330 for primary prostate 
epithelial cells. In 0 mM Ca2+ solution CaCl2 was omitted 
and in divalent free solution (DVF) MgCl2 and CaCl2 were 
replaced by 10 mM EDTA, osmolarity was adjusted to 330 
mosmol/L with glucose. In 2-APB experiments 2-APB 
was added as indicated. Pipette solution contained in mM: 
120 Cs glutamate, 10 BAPTA, 10 HEPES, 3 MgCl2 and 
0.05 IP3 for LNCaP cells and 140 Cs glutamate, 8 NaCl, 
10 BAPTA, 10 HEPES, 3 MgCl2 and 0.05 IP3 for hPEC. 
For reasons of comparability DU145 and LNCaP in Fig. 3 
and S3 were patched under the same conditions as hPEC.
Data analysis and statistics
Data were analyzed with TILLVision (TILL 
Photonics), Fitmaster 2.35 (HEKA), Igor Pro 
(Wavemetrics), and Microsoft Excel (Microsoft). Data 
are given as means ± SEM. Asterisks indicate significance 
determined by an unpaired, two-sided Student’s t-test *p 
< 0.05, **p < 0.01, ***p < 0.001. Significance of changes 
in PSA release assays was tested with a one-sided unpaired 
t-test. Significance of changes of relative gene expression 
in tissue probes from patients was analyzed with a paired 
t-test. EC50 and IC50 values were determined by a fit with 
Hill’s equations (least-squares method). For qRT-PCR 
relative expression was calculated according to the ∆Cq 
method (2−∆Cq) where Cq values are determined with the 
MX3000 software and excluded from analysis when they 
exceeded 35 cycles.
Small interfering RNA transfection (siRNA)
SiRNA tranfections were perfomed with 0.12 nmol 
of siRNA with a Nucleofector II (Lonza) nucleofector 
using Nucleofector transfection Kit R (Lonza) according to 
manufacturer’ instructions. All siRNAs were from Qiagen 
or Microsynth and were in part modified according to [69]. 
Orai1 siRNAs were Hs_TMEM142A_1, #SI03196207 
[sense: 5’OMeC-OMeG-GCCUGAUCUUUAU CG-
d (UCU) OMeU-OMeT-OMeT3’; antisense: 3’OMeG-
OMeC-CGGACUAGAAA UA GCAGAd(A)5’] 
and Hs_TMEM142A_2, #SI04215316 [sense: 
5’OMeC-OMeA-ACAUCGAGGCG GUG A)d(GCA)
OMeA-OMeT-OMeT3’; antisense: 3’OMeG-OMeT-
UGUAGCUCCGCCA CUCGUd(U)5’]. Orai3 siRNAs 
were Hs_TMEM142C_2, # SI04174191 [sense: 
5′OMeC-OMe A-CCAGUGGCUACCUCCd(CUU)
OMeA-OMeTOMeT3′; antisense: 3′OMeG-
OMeT -GG UCACCGAUGGAGGGAAd(U)5′] 
and Hs_TMEM142C_5, #SI04348876 [sense: 
5′OMeT-OMeC-CUU AGCCCUUGAAAU)d(ACA)
OMeA-OMeT-OMeT3′; antisense: 3′OMeA -OMeG-GA-
A U CGGGAACUUUAUGUd(U)5′]. STIM1 siRNAs 
were Hs_STIM1_5, # SI03235442 [sense: 5’OMeU-
OMeGAGG UGGAGGUGCAAUd(AUU)dOMeA-
dOMeT-dOMeT3′; antisense: 3’OMeA-OMeC-U C-
CACCUCCACGUUAUAAd(U)5’] and Hs_STIM1_6, # 
SI04165175 [sense: 5’OMeC-OMeU-GGUGG UGUCU-
A UCGUd(UAU) OMeU-OMeT-OMeT3’; antisense: 
3’OMeG-OMeA-CCACCA CA G AUAGCAAUAd(A)5’]. 
STIM2 siRNAs were Stim2_6 (Microsynth), 
[sense: 5’UAAGCAGCAUCCCACAU GAdT d T 3’; 
antisense:  3’dTdTAUUCGUCGUAGGGUGUACU5’] 
and Stim2_7 (Microsynth), [sense : 5’AAUUUAGAG-
CGCAAAAU GAdTdT3’; antisense: 3’dTdTUUAA-
AUCU CGCGUUUUACU5’] and Stim2_8 (Microsynth) 
[sense: 5’GUGCACGAACCUUCAU U U A d Td T3’; 
antisense: 3’dTdTCACGUGCUUGGAAGUAAAU5’]. 
Non-silencing RNA were MS_control_mod [sense: 
5’OmeA-OMeA-AGGUAGUGUAAUCGCd(CUU)
OMeG-OmeT-OMeT3’; antisense: 3’OmeT-OmeT-
UCCAUCACAUUAGCGGAAdC 5’].
Determination of prostate specific antigen (PSA)
LNCaP cells were transfected with either control or 
Orai1 specific siRNA and seeded in 6-well plates. After 
24 h medium was replaced by hormone deprived medium 
for 48 h. After 100 nM DHT has been added, 250 µl of 
supernatant was removed at the time points indicated 
and total PSA within the supernatant was determined in 
an ECLIA (ElectroChemiLuminescence ImmunoAssay) 
using a cobas system (Roche). PSA was determined in ng/
mL and normalized to 106 cells.
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